LXRX Stock Summary and Trading Ideas (Lexicon Pharmaceuticals | NASDAQ:LXRX)

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Lexicon Pharmaceuticals trades on the NASDAQ stock market under the symbol LXRX.

As of April 4, 2025, LXRX stock price declined to $0.42 with 9,932,418 million shares trading.

LXRX has a beta of 3.46, meaning it tends to be more sensitive to market movements. LXRX has a correlation of 0.15 to the broad based SPY ETF.

LXRX has a market cap of $151.43 million. This is considered a Micro Cap stock.

Last quarter Lexicon Pharmaceuticals reported $27 million in Revenue and -$.09 earnings per share. This beat revenue expectation by $20 million and exceeded earnings estimates by $.03.

In the last 3 years, LXRX traded as high as $3.79 and as low as $.28.

The top ETF exchange traded funds that LXRX belongs to (by Net Assets): VTI, VXF, IWM, VHT, SCHA.

LXRX has underperformed the market in the last year with a return of -79.5%, while the SPY ETF lost -1.3%. In the last 3 month period, LXRX fell short of the market, returning -46.9%, while SPY returned -14.4%. However, in the most recent 2 weeks LXRX has outperformed the stock market by returning +21.5%, while SPY returned -10.1%.

LXRX support price is $.41 and resistance is $.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LXRX shares will trade within this expected range on the day.